Evidence map›Paper›PMID 41280238›Full record

ArticleJournal of pharmaceutical policy and practice2025

Bioequivalence centres in Africa: current state and opportunities for growth.

Bakani Mark Ncube, Sarah Muthuri, Olawale Ajose, Loice Kikwai

Abstract read
In one paragraph

Article in Journal of pharmaceutical policy and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bakani Mark NcubeMarket Access Africa, Geneva, Switzerland.ORCID https://orcid.org/0000-0002-8311-0752
Sarah MuthuriMarket Access Africa, Geneva, Switzerland.
Olawale AjoseMarket Access Africa, Geneva, Switzerland.ORCID https://orcid.org/0000-0002-6177-622X
Loice KikwaiMarket Access Africa, Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bioequivalence studies are required for generic medicines to meet the same quality, safety, and efficacy standards as innovator products before receiving marketing authorisation. These studies compare the in vivo performance of a generic medicine to that of the innovator product. Two products are bioequivalent if they are pharmaceutically equivalent and have similar bioavailabilities (C

Indexed as

bioavailabilityBioequivalenceglobal benchmarking toolLocal pharmaceutical productionnational medicines regulatory authorityregulatory systems strengthening

Identifiers

PMID41280238
PMCPMC12636534

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.